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Gregory L. Moneta, MD, Section EditorEffects of Intensive Medical Therapy on Microemboli and Cardiovas-
cular Risk in Asymptomatic Carotid Stenosis
Spence JD, Coates V, Li H, et al. Arch Neurol 2010;67:180-6.
Conclusion: Less than 5% of patients with asymptomatic carotid
stenosis will benefit from revascularization. Patients with asymptomatic
carotid stenosis should receive intensive medical therapy and only be con-
sidered for revascularization if microemboli are demonstrated by transcranial
Doppler (TCD) imaging.
Summary: The principle cardiovascular event in patients with asymp-
tomatic carotid stenosis is myocardial infarction rather than stroke (Stroke
1994;25:759-65). Randomized trials have demonstrated a reduction in late
stroke with carotid endarterectomy for asymptomatic high-grade carotid
stenosis, with a high number needed to treat to prevent one stroke. In
addition, the benefit of surgery in these trials occurred in an era of less
intense medical therapy than what is prevalent now. The authors previously
reported that TCD detection of microemboli is useful in identifying patients
with asymptomatic carotid stenosis who might be candidates for revascular-
ization. The authors noted, however, that patients with asymptomatic
carotid stenosis with detectable microemboli by TCD have become fewer in
number in the last few years. They hypothesized that the incidence of
microemboli has been reduced through a possible mechanism of stabiliza-
tion of carotid plaques with more intensive medical therapy.
This study was designed to compare the proportion of asymptomatic
carotid stenosis patients with TCD-determined microemboli, cardiovascular
events, and carotid plaque progression correlated with baseline medical
therapy before and after 2003. The study involved 468 patients collected
prospectively with asymptomatic carotid stenosis 60% as determined by
duplex scanning. Of the 468 patients, 199 were enrolled between January 1,
2000, and December 31, 2002, and 269 were enrolled between January
2003 and July 2007. Before 2003, microemboli were present in 12.6% and
since 2003 were present in only 3.7% (P  .001). Declining numbers of
patients withmicroemboli correlated with better control of plasma lipids and
slower progression of carotid plaque area. Before 2003, 17.6% of patients
had stroke, death, myocardial infarction, or carotid endarterectomy for
symptoms. Since 2003, only 5.6% have had stroke, death, myocardial
infarction, or carotid endarterectomy for symptoms (P  .001). In the first
year of follow-up before 2003, the rate of carotid plaque progression
declined from 69 mm2 (standard deviation, 96 mm2) to 23 mm2 (standard
deviation, 86 mm2, P  .001) after 2003.
Comment: The tone of this article is clearly biased against intervention
of any sort for high-grade asymptomatic carotid stenosis. The literature cited
by the authors for stroke rates with asymptomatic carotid stenosis treated by
endarterectomy or carotid stenting are on the very high end of the published
ranges. Nevertheless, the authors are probably correct that modern medical
management of patients with asymptomatic carotid stenosis likely by itself
lowers the potential benefit of intervention added to medical management.
The current approach for management of patients with high-grade asymp-
tomatic carotid stenosis in the United States is essentially to offer interven-
tion to most patients based on the presence of a duplex-detected high-grade
stenosis. This approach is coming under increasing question and scrutiny
and is certainly not the approach used throughout much of the world
outside the United States. There is currently no agreement on how to best
select these patients for intervention. The authors suggest screening with
TCD, and others suggest using magnetic resonance characteristics of the
plaque or even ultrasound plaque characterization. It seems unlikely that
another large randomized trial of intervention vs no intervention for asymp-
tomatic carotid stenosis will be conducted and completed anytime in the
near future. For now, selection of patients with asymptomatic carotid
stenosis for intervention will likely remain center-specific and confined
primarily to the United States.
Factors that Predict Risk of Thrombosis in Relatives of Patients with
Unprovoked Venous Thromboembolism
Couturaud F, Leroyer C, Julian JA. Chest 2009;136:1537-45.
Conclusion:Unprovoked venous thromboembolism (VTE) occurring
at a young age is associated with increased risk of VTE in families of patients
with VTE.
Summary: About one-quarter of all VTE is idiopathic or “unpro-
voked.” One-third of these patients will have identified genetic predisposi-
tions to thrombosis. The factor V-Leiden and G20210A prothrombin gene
mutations account for 90% of detected genetic abnormalities (Lancet 2003;
138:19-25). If a genetic mutation is not identified in a patient with VTE, it
is often assumed that relatives do not have increased risk of thrombosis. Such
1584an assumption may not be true, however, because it is likely there are many
causes of heredity thrombophilia that have yet to be discovered. The
authors’ primary hypothesis was at the risk of VTE would be similar in
families of patients who had factor V-Leiden or the G20210A prothrombin
gene mutation compared with relatives of patients with neither of these two
abnormalities. The authors assumed that most patients with unprovoked
VTE, who have negative tests for thrombophilia, do in fact have hereditary
defects that have yet to be discovered and that these abnormalities would
increase the risk of thrombosis in the patient’s first-degree relatives.
This was a cross-sectional study. Investigators were blinded to whether
patients or their relatives had thrombophilia. The prevalence of previous
venous VTE in 1916 first-degree relatives of 348 unselected patients with a
first episode of unprovoked VTE was investigated. Patient characteristics
and the presence of factor V-Leiden or the G20210A prothrombin gene
mutation was assessed as predictors of VTE in the patient’s first-degree
relatives.
The first-degree relatives had sustained 102 previous episodes of VTE
(prevalence 5.3%). Patient thrombosis at a young age was the strongest
predictor of VTE in relatives. There was an odds ratio (OR) of 3.27 (95%
confidence interval [CI], 1.68-6.38) for younger patients (patients aged
45 when VTE occurred; lowest quartile) compared with older patients
(patients aged 71; highest quartile). The presence of factor V-Leiden or
G20210A prothrombin gene mutation was a weak independent predictor of
VTE in relatives (adjusted OR, 1.48; 95% CI, 0.94-2.33).
Comment: The data indicate that the age of patients with unprovoked
VTE is probably the single best way to stratify the risk of VTE in those
patients’ families. Testing for factor V-Leiden or the G20210A prothrombin
gene mutation in a patient with unprovoked VTE has limited ability to
predict VTE in first-degree relatives. The data also provide indirect evidence
that there are undiscovered hereditary thrombophilic abnormalities in many
patients with unprovoked VTE.
“Hybrid” Repair of Aneurysms of the Transverse Aortic Arch: Mid-
term Results
Hughes GC, Daneshmand MA, Balsara KR, et al. Ann Thorac Surg 2009;
88:1882-8.
Conclusion: Hybrid repair of transverse aortic arch aneurysms at
midterm follow-up is safe and effective.
Summary: A combination of endovascular and open surgical ap-
proaches to the treatment of transverse arch aneurysms has been described
(Ann Thorac Surg 2008;86:1524-9; J Thorac Cardiovasc Surg 2008;136:
21-8). Potential advantages of the hybrid approach include lower perioper-
ative morbidity and mortality and single-stage treatment of some patholo-
gies that previously required a two-stage repair. At the authors’ institution
betweenMarch 2005 andOctober 2008, 178 thoracic endograft procedures
were performed, of which 28 (16%) were hybrid arch repairs. Indications
included saccular aneurysm (n 11) and fusiform aneurysm (n 17) of the
transverse arch. The aneurysm in 10 patients (36%) was secondary to aortic
dissection in patients with 2 cm of proximal landing zone distal to the
innominate artery. In these cases, a right-to-left carotid-carotid bypass was
performed to create a proximal landing zone covering the left carotid origin.
For 12 patients with mid arch aneurysms and 2 cm of proximal landing
zone in the ascending aorta, proximal ascending aorta-based arch debranch-
ing was performed. In patients with arch aneurysms without an adequate
proximal landing zone were with an adequate distal landing zone, a one-
stage elephant trunk procedure was used to create a proximal landing zone.
Procedures were staged in the group receiving an initial elephant trunk
procedure but were performed at the same setting in the other two groups.
The mean patient age was 64  13 years. Technical success was achieved in
100%. The 30-day and in hospital death, stroke, and permanent paraplegia
paresis rates were 0%, 0% and 3.6%, respectively. No late aortic related events
have occurred at a mean follow-up of 14  11 months. Two type 1
endovascular leaks required a secondary endovascular intervention.
Comment: In expert hands, total arch replacement with traditional
techniques frequently requires deep hypothermic circulatory rest, often a
two-stage procedure, and has perioperative death or stroke rates approach-
ing 15% (Ann Thorac Surg 2007;83 [suppl]:815-8). Comparatively, the
current results with hybrid procedures seem improved. The approach has
several potential technical advantages. Cardiopulmonary bypass is generally
not needed, and simultaneous treatment of arch and descending thoracic
lesions, which previously required a two-stage repair with elephant trunk
procedures, can be performed sooner, given the smaller magnitude of the
endovascular component. The authors note that using existing Dacron
grafts for proximal landing zonesmaybe problematic. Type 1 endoleak for such
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the well-known tendency for Dacron to dilate over time may be accentuated
by the presence of an endograft. They suggest oversizing the endograft 20%
and a proximal landing zone with at least 4 cm of overlap when the graft is
landed in Dacron.
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous
Thromboembolism Prevention Trials
Eikelboom JW,QuinlanDJ, O’Donnell M. Circulation 2009;120:2006-11.
Conclusion: Major bleeding in hospitalized patients participating in
venous thromboembolism (VTE) prevention trials is a strong predictor of
mortality.
Summary: Emerging evidence suggests bleeding is a strong predictor
of death in patients with acute arterial thrombosis receiving antithrombotic
therapy (Eur Heart 2007;28:1193-204; Neurology 2008;71:650-5). It is,
however, unknown whether a similar association exists between bleeding
and death in patients with VTE. The authors used a fondaparinux VTE
prevention database to explore associations between major bleeding and
death, with adjustments for other patient characteristics. Analysis of the
fondaparinux database was provided by GlaxoSmithKline. The database
consisted of all phase 3 randomized controlled trials comparing fondapa-
rinux (2.5 mg once daily) with low- molecular-weight heparin or placebo for
prevention of VTE. The trials included 13,085 patients undergoing hip
replacement surgery, major knee surgery, or elective abdominal surgery, and
also high-risk medical patients. Major bleeding was defined as retroperito-
neal, intracranial, or intraspinal bleeding; any bleeding that involved a critical
organ or led to reoperation, or overt bleeding with a bleeding index
(calculated as the number of packed red blood cells or whole blood trans-
fusions plus pre- bleeding hemoglobin concentration minus post bleeding
hemoglobin concentration)2. The primary outcome variable was death in
30 days.
Patients who developed major bleeding were older, more likely to be
male, had a lower body mass index and lower creatinine clearance, and were
more likely to be receiving fondaparinux. At 30 days, the risk of death was
sevenfold higher among patients with a major bleeding event (8.6% vs 1.7%;
adjusted hazard ratio [HR], 6.96; 95% confidence interval [CI], 4.6-10.5).
However, fondaparinux was associated with a decreased mortality rate in the
patients experiencing major bleeding (6.8% vs 11.4%; HR, 0.58; 95% CI,
0.27-1.23).
Comment: This article has three findings of particular interest. First,
lower body weight, male sex, and renal dysfunction are predictors of major
bleeding in patients enrolled in VTE prevention trials. Second, major
bleeding in patients enrolled in these trials is associated with a sevenfold
increased mortality rate at 30 days. Finally, fondaparinux, although associ-
ated with an increased risk of bleeding, appeared to be associated with a
decreased risk of death with major bleeding compared with major bleeding
associated with other antithrombotic agents. The data are consistent with
previous studies showing an association between major bleeding and death
in patients treated with antithrombotic agents for acute coronary syndromes
and ischemic stroke. Only 6% of the deaths in this analysis were directly
attributed to the bleeding episode. The precise reasons for increased death in
patients who develop major bleeding while being treated with anticoagula-
tion agents remain to be determined.
Open Abdominal Aortic Aneurysm Repair in the Endovascular Era:
Effect of Clamp Site on Outcomes
Landry G, Lau I, Liem T, et al. Arch Surg 2009;144:811-6.
Conclusion: Suprarenal cross clamping during open abdominal aortic
aneurysm (AAA) repair is associated with increased rates of complications
but similar mortality rates and need for nursing home placement as open
abdominal aortic aneurysm (AAA) repair with infrarenal clamping.
Summary: Currently, the most frequent anatomic restriction for use of
the endovascular aneurysm repair (EVAR) is an inadequate infrarenal neck
to achieve proximal fixation. Although performed “under the table” in some
centers, in only a few centers in the United States is fenestrated endografting
currently performed with actual investigational device exemptions (IDEs).
Therefore, AAAs with an inadequate proximal fixation zone still need open
AAA repair in most centers. This is a study of contemporary series of open
AAA repairs in patients who were not considered suitable candidates for
EVAR.
Patients were derived from those undergoing open repair during the
endovascular era. Consecutive nonruptured open aneurysm repairs from
March 1, 2000, through July 31, 2007, were reviewed. There were 185
patients who underwent 103 infrarenal and 82 suprarenal cross-clamp
repairs. The occurrence of any complication was 37%with infrarenal and 61%
for suprarenal cross-clamp repairs (P  .001). The 30-day mortality was
2.9% for AAA repair with an infrarenal cross clamp and 6.1% for AAA repair
with a suprarenal cross clamp (P  .18). Complications that occurred most
frequently in the suprarenal cross-clamp group were postoperative renal
insufficiency and pulmonary complications. Suprarenal cross clamps werealso associated with greater intraoperative blood loss, operative duration,
and use of adjunctive renal or visceral grafts. Intensive care units and hospital
lengths of stay were also longer in the suprarenal cross-clamp group. Patients
undergoing suprarenal cross clamp had a 25.6% rate of temporary nursing
home placement vs 17.5% in those patients treated with an infrarenal cross
clamp (P  .14).
Comment: At some point it is almost inevitable that open AAA surgery
will, for the most part, be relegated to the to the dust bin. When this actually
happens will depend on a slew of regulatory, engineering, technical, and cost
considerations. In the interim, some AAAs will still need to be repaired with
open techniques. The data indicate what is well known: Open repair is
associated with significant morbidity, but mortality rates are low. Open
repairs of AAA are, at the same time, becoming more infrequent and more
complex.With the limited training available in these complex repairs inmany
vascular surgical residencies, it may not be appropriate for most finishing
vascular surgical trainees to perform open AAA repair right out of residency
without senior colleague supervision. On the other hand, it is also very likely
not to be appropriate for older vascular surgeons to perform fenestrated
endografts without junior colleague supervision!
Quality of Life in Patients with Idiopathic Subclavian Vein Thrombosis
Berzaczy D, Popovic M, Reiter M, et al. Thromb Res 2010:125:25-8.
Conclusion: Patients with idiopathic subclavian vein thrombosis treated
without surgical or catheter based intervention have good overall quality of
life and deal well with their physical limitations.
Summary: Late clinical manifestations of axillosubclavian vein throm-
bosis can be persistent swelling and the presence of prominent veins on the
chest wall in 7% to 46% of patients (Thromb Res 2005;117:609-14). The
authors sought to determine how quality of life was affected after idiopathic
subclavian vein thrombosis using the Short Form (SF)-36 survey and the
Disabilities of the Arm, Shoulder and Hand (DASH) outcome question-
naire. The DASH, which was introduced in 1994 by the American Academy
of Orthopedic surgeons, is a self-administered questionnaire of 30 questions
designed to measure upper extremity disability and symptoms. It appears to
be an accurate measure of disability irrespective of underlying cause (J Hand
Therapy 2001;14:128-46). The intent was to assess thrombosis-related
disability of the upper extremity and general quality of life in patients who
had had axillosubclavian vein thrombosis. The DASH and SF-36 both use
100-point scales. In DASH, 0 represents uncompromised function and 100
is maximum limitation; whereas in the SF36, 0 is the lowest rating quality of
life and 100 indicates the best imaginable quality of life.
The patients had been treated with anticoagulation alone or systemic
thrombolysis, followed by anticoagulation. They did not appear to be
treated with catheter-directed thrombolysis or surgical decompression of the
thoracic outlet. Mean follow up was 120  80 months. Right-sided subcla-
vian vein thrombosis occurred in 22 patients (60%) and left-sided subclavian
vein thrombosis occurred in 14 (40%). Anticoagulant therapy was used for
12 months after initial presentation in 92% and for12 months in 8%. At
follow-up, arm swelling was present in 43% of patients, venous ectasias in
54%, pain at rest in 16%, and pain with exercise in 22%. Despite these
findings, mean DASH and SF-36 scores were good, with a mean DASH
score of 10.7  12 and mean scores for the SF-36 physical component
summary and mental component system of 52  9.3 and 46  9.5,
respectively.
Comment: These data provide long-term information on symptoms
and signs after conservatively managed idiopathic axillosubclavian vein
thrombosis and the effects of these signs and symptoms on patient-perceived
function and quality of life. Advocates of invasive management of subclavian
vein thrombosis will point to the high prevalence of late symptoms and signs
related to the subclavian vein thrombosis. Those favoring more conservative
management will note, despite the presence of arm swelling and symptoms,
the patients actually had little functional impairment and a very reasonable
quality of life. In either case, the data suggest it may be difficult to demon-
strate significant patient-perceived improvement with surgical therapy over
medical management alone in patients with axillosubclavian vein thrombo-
sis.
The General Prognosis of Patients with Peripheral Arterial Disease
Differs According to the Disease Localization
Aboyans V, Desormais I, Lacroix P, et al. J Am Coll Cardiol 2010;55:898-
903.
Conclusion: Independent of risk factors and other comorbidities, in
patients with peripheral arterial disease (PAD), there is a poorer overall
general prognosis in patients with proximal (aortoiliac) disease compared
with those with more distal PAD.
Summary: Cardiovascular risk factors, socioeconomic, and demo-
graphic differences are associated with different patterns of peripheral arterial
disease (PAD) and progression rates of PAD differ between large and small
vessels. Distal PAD is associated with more adverse outcomes with respect to
the limb itself. The general belief, with little direct evidence, is also that more
